Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 3959  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (37 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  Discussion
 ::  References

 Article Access Statistics
    Viewed4284    
    Printed126    
    Emailed1    
    PDF Downloaded148    
    Comments [Add]    
    Cited by others 6    

Recommend this journal


 


 
ADR REPORT
Year : 2008  |  Volume : 54  |  Issue : 3  |  Page : 233-234

Gatifloxacin-induced rhabdomyolysis


1 Department of Internal Medicine, Christian Medical College and Hospital, Ludhiana - 141 008, India
2 Department of Nephrology, Christian Medical College and Hospital, Ludhiana - 141 008, India
3 Department of Pharmacology, Christian Medical College and Hospital, Ludhiana - 141 008, India

Correspondence Address:
P George
Department of Internal Medicine, Christian Medical College and Hospital, Ludhiana - 141 008
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0022-3859.41813

Rights and Permissions




How to cite this article:
George P, Das J, Pawar B, Badyal D. Gatifloxacin-induced rhabdomyolysis. J Postgrad Med 2008;54:233-4

How to cite this URL:
George P, Das J, Pawar B, Badyal D. Gatifloxacin-induced rhabdomyolysis. J Postgrad Med [serial online] 2008 [cited 2019 May 19];54:233-4. Available from: http://www.jpgmonline.com/text.asp?2008/54/3/233/41813


Flouroquinolone antibiotics cause musculoskeletal adverse effects like myalgia, arthralgia, tendon disorders and rhabdomyolysis. [1] Ofloxacin and levofloxacin rarely cause rhabdomyolysis, [2] but gatifloxacin has not yet been reported to cause rhabdomyolysis.

A 50-year-old male was admitted with intermittent fever and lower urinary tract symptoms for two days. No oliguria or dark urine was noticed. No alcohol abuse, illicit drugs, unprescribed medication use, unaccustomed exercise or trauma was present. A routine health evaluation two months prior was normal. Clinical examination at admission was unremarkable.

Renal failure (blood urea 52 mg/dl, serum creatinine 3.2 mg/dl, serum potassium 5.8 meq/dL, metabolic acidosis) with leucopenia (total leucocyte count 3200/mm 3 ) was observed. Bacteriuria was present on urine microscopy (urine white blood cells 60/HPF). Leptospira antibodies were negative. Ultrasonography of the kidneys was normal. He was treated with intravenous gatifloxacin 200 mg once daily.

The renal failure worsened over the next three days (blood urea 100 mg/dl, serum creatinine 5.5 mg/dl, worsening metabolic acidosis) and he complained of severe muscular pain and weakness. Grade 4 muscle power with generalized muscle tenderness and an inability to sit up, stand or walk unsupported was noticed. The serum muscle enzymes were elevated [creatinine phosphokinase (CPK) 5915 U/L, lactate dehydrogenase (LDH) 1466 U/L, serum glutamic oxaloacetic transaminase (SGOT) 364 U/L.] Urine and serum myoglobin were not significantly raised. Hypocalcemia (serum calcium 6.6 mg/dl), hypophosphatemia (2 mg/ dL), hyperuricemia (serum uric acid 10.4 mg/dL) and thrombocytopenia (platelet count 96000/cu mm) developed. Creatinine phosphokinase peaked at 7314 U/L. Electromyography did not show evidence of myopathy.

Gatifloxacin-induced rhabdomyolysis was considered and intravenous cefoperazone/sulbactam 1 g twice daily was used instead, along with rehydration and furosemide-alkaline diuresis. Twenty-four hours after stopping gatifloxacin, his renal functions improved and a downward trend of muscle enzymes was noticed. Five days later his renal function normalized and the muscle enzymes declined significantly (CPK 304 U/L, LDH 751 U/L, SGOT 145 U/L) with resolution of all muscle symptoms. He was discharged with a word of caution on future use of quinolones. He did not come for review subsequently.


 :: Discussion Top


The distinctive clinical presentation and temporal association of gatifloxacin with symptoms, biochemistry values and subsequent improvement after withdrawal suggested that rhabdomyolysis in this patient was gatifloxacin-induced. An objective assessment by the use of Naranjo probability scale two days after stopping gatifloxacin revealed a score of six, indicating drug-related rhabdomyolysis. [3] Drugs directly or indirectly impairing the production and use of adenosine triphosphate (ATP) by skeletal muscle or increasing energy requirements exceeding the rate of ATP production, can cause rhabdomyolysis. [4] The clinical profile and investigations did not suggest attributable infective causes for rhabdomyolysis (sepsis, pyomyositis, dengue fever and infection with Legionella,  Salmonella More Details, Falciparum malaria, Influenza or HIV). [5] The early onset of rhabdomyolysis in this patient suggested a direct effect on muscles and collagen fibers by gatifloxacin. Adverse effects of fluoroquinolones appear to be class-mediated or due to structural modification. Structure-side-effect relationships of substitution in quinolones show phototoxicity at positions R 5 and X 8 , genetic toxicity at R 1 , R 5 , R 7 and X 8 and theophylline interaction at R 1 and R 7 . [6] A review of the literature showed no previous association of rhabdomyolysis with gatifloxacin.

Presentation in rhabdomyolysis may vary from an asymptomatic illness (with only elevation in CPK) to a life-threatening condition associated with extreme elevations in CPK (levels more than 5000 U/L indicate serious muscle injury), acute renal failure and disseminated intravascular coagulation. [7] Other important biochemical findings include hyperkalemia, hypocalcemia, hyperphosphatemia, hyperuricemia, metabolic acidosis and raised levels of other muscle enzymes including lactate dehydrogenase, aldolase, aminotransferases, and carbonic anhydrase III. [1],[7]

The patient responded well to conservative management of acute renal failure and rhabdomyolysis after stopping gatifloxacin.

 
 :: References Top

1.Poels PJ, Gabreels FJ. Rhabdomyolysis: A review of the literature. Clin Neurol Neurosurg 1993;95:175-92.  Back to cited text no. 1    
2.Hsiao SH, Chang CM, Tsao CJ, Lee YY, Hsu MY, Wu TJ. Acute rhabdomyolysis associated with ofloxacin-levofloxacin therapy. Ann Pharmacother 2005;39:146-9.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al . A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 3  [PUBMED]  
4.Knochel JP. Mechanisms of rhabdomyolysis. Curr Opin Rheumatol 1993;5:725-31.  Back to cited text no. 4  [PUBMED]  
5.Lee VWS, Harris D, Anderson RJ, Schrier RW. Acute renal failure. In: Schrier RW, editor. In diseases of the kidney and urinary tract. Vol 2. 8 th ed. Philadelphia: Lippincott, Williams and Wilkins; 2007. p. 1001.  Back to cited text no. 5    
6.Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis 1999;28:352-64.  Back to cited text no. 6  [PUBMED]  
7.Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis-an overview for clinicians. Crit Care 2005;9:158-69.  Back to cited text no. 7    



This article has been cited by
1 Ventilator-associated pneumonia caused by OXA-48-producing Escherichia coli complicated by ciprofloxacin-associated rhabdomyolysis
Andrea J. Grisold,Martin Hoenigl,Ismar Ovcina,Thomas Valentin,Sonja Fruhwald
Journal of Infection and Chemotherapy. 2013;
[Pubmed] | [DOI]
2 Moxifloxacin-induced rhabdomyolysis
S. Sanjith, A. Raodeo, A. Clerk, R. Pandit, D. R. Karnad
Intensive Care Medicine. 2012;
[VIEW] | [DOI]
3 Musculoskeletal Complications of Fluoroquinolones: Guidelines and Precautions for Usage in the Athletic Population
Mederic M. Hall,Jonathan T. Finnoff,Jay Smith
PM&R. 2011; 3(2): 132
[Pubmed] | [DOI]
4 Facilitating adverse drug event detection in pharmacovigilance databases using molecular structure similarity: Application to rhabdomyolysis
Vilar, S. and Harpaz, R. and Chase, H.S. and Costanzi, S. and Rabadan, R. and Friedman, C.
Journal of the American Medical Informatics Association. 2011; 18(SUPPL. 1): 73-80
[Pubmed]
5 Miscellaneous antibacterial drugs
Corti, N. and Imhof, A. and Wenger, C.
Side Effects of Drugs Annual. 2010; 32: 461-489
[Pubmed]
6 Current awareness: Pharmacoepidemiology and drug safety
Pharmacoepidemiology and Drug Safety. 2009; 18(1): i
[VIEW] | [DOI]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow